Robert Radie

Biography

Timothy Walbert Chairman Mr. Walbert has been a member of our board of directors since March 2014 and has served as our chair since June 2015. Mr. Walbert has been the president and chief executive officer of Horizon Pharma since June 2008 and has been the chairman of the Horizon board since 2010. Previously, he served as president, chief executive officer, and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Mr. Walbert served as executive vice president, commercial operations, at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, Mr. Walbert served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA, which is on track to exceed $10.0 billion in 2013 sales, and divisional vice president, global cardiovascular strategy, at Abbott, now AbbVie. From 1998 to 2001, Mr. Walbert served as director, CELEBREX North America, and arthritis team leader, Asia Pacific, Latin America, and Canada at G.D. Searle & Company. From 1991 to 1998, Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc., and Wyeth. Mr. Walbert received his B.A. in business from Muhlenberg College. In addition to the Egalet board of directors, Mr. Walbert serves on the XOMA Ltd., Sucampo Pharmaceuticals, Inc., Biotechnology Industry Organization (BIO), Illinois Biotechnology Industry Organization (iBIO), ChicagoNEXT and Greater Chicago Arthritis Foundation boards. Mr. Walbert was appointed by Illinois Governor Pat Quinn to the Illinois Innovation Council. Elaine Hochberg Ms. Hochberg has served as a member of our board of directors since April 2017. Ms. Hochberg has been the managing partner of Elaran, LLC, a business strategy and management firm, since 2016. She served in various positions of increasing responsibility at Forest Laboratories, LLC from 1997 to 2014, including as executive vice president – international, strategic planning and government affairs from 2013 to 2014, as executive vice president – US sales and marketing from 2010 to 2013 and as chief commercial officer from 2007 to 2013. Prior to that, Ms. Hochberg served in various roles at Wyeth Ayerst Laboratories. She serves on the board of Akcea Therapeutics, Inc., as well as the boards of several nonprofit corporations. Ms. Hochberg earned her BA and MBA from Columbia University. Nicholas Nicolaides, PhD Dr. Nicolaides has been on our board of directors since joining in April of 2015. He is the president and co-founder of Morphotek, a biopharmaceutical company specializing in the development of protein and antibody products for treating cancer, inflammation and infectious disease. Dr. Nicolaides’ post-graduate research at Johns Hopkins Medical School was the basis for the company’s inception. In the spring of 2007, Morphotek was acquired by Eisai Co. Ltd, a global health care pharmaceutical company. Prior to co-founding Morphotek, Dr. Nicolaides was the director of research at Magainin Pharmaceuticals, where his research focused on the development of bio-therapeutics to treat respiratory disease. He is a trained molecular geneticist and has authored a number of scientific papers on the molecular and genetic basis of cancer and respiratory diseases. He received his B.S. in biology at St. Joseph’s University, his Ph.D. in human genetics at Thomas Jefferson University and continued his training as a Fellow in Oncology at Johns Hopkins University. Dr. Nicolaides is an author on more than 50 original publications and is an inventor on numerous patents for developing bio-based therapies and therapeutic compositions. John Osborn Mr. Osborn has been a member of our board of directors since joining in April 2015. An experienced life sciences industry executive, Mr. Osborn was general counsel for a decade with Fortune 1000 biopharmaceutical company Cephalon, Inc. and held senior posts with Onyx Pharmaceuticals, Dendreon, US Oncology and DuPont Merck Pharmaceuticals. He has substantial experience in government affairs and public policy, having served with the U.S. Department of State during the George H.W. Bush administration, and from 2008 to 2011 he was a member of the bipartisan United States Advisory Commission on Public Diplomacy. Mr. Osborn currently is a senior advisor with the international law firm Hogan Lovells, and an industry advisor with the healthcare and consumer group of the global private equity firm Warburg Pincus. He has held faculty appointments at Oxford, Princeton and the University of Washington, and is a member of the Council on Foreign Relations, the American Law Institute, the advisory boards of QPID Health, Inc. and the University of Michigan Life Sciences Institute. Mr. Osborn received his undergraduate degree in economics and history from the University of Iowa, his law degree from the University of Virginia School of Law, and his master’s degree in international public policy from The Johns Hopkins University School of Advanced International Studies. Robert Radie Mr. Radie is president, chief executive officer and a member of Egalet’s board of directors and has been since March 2012. Mr. Radie has had a successful career with more than three decades in the industry and has been responsible for the sale of five companies. In 2005 Mr. Radie led the sale of Vicuron Pharmaceuticals to Pfizer for $1.9 billion and most recently he was responsible for the sale of Topaz Pharmaceuticals Inc. to Sanofi Pasteur for an undisclosed amount. Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Prestwick Pharmaceuticals, Inc., Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and served as a director of Affinium Pharmaceuticals, Ltd. from July 2012 to March 2014, when a majority of Affinium’s assets were acquired by a third party. Mr. Radie began his career in the life sciences at Eli Lilly and Company where he worked for 18 years in sales and marketing positions with increasing levels of responsibility. Mr. Radie serves on the board of Paratek Pharmaceuticals, a biopharmaceutical company, Pennsylvania Bio, an industry group supporting Pennsylvania life sciences companies, Veloxis, a private commercial-stage company, and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. Mr. Radie received his B.S. in chemistry from Boston College.

Research Interest

Timothy Walbert Chairman Mr. Walbert has been a member of our board of directors since March 2014 and has served as our chair since June 2015. Mr. Walbert has been the president and chief executive officer of Horizon Pharma since June 2008 and has been the chairman of the Horizon board since 2010. Previously, he served as president, chief executive officer, and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Mr. Walbert served as executive vice president, commercial operations, at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, Mr. Walbert served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA, which is on track to exceed $10.0 billion in 2013 sales, and divisional vice president, global cardiovascular strategy, at Abbott, now AbbVie. From 1998 to 2001, Mr. Walbert served as director, CELEBREX North America, and arthritis team leader, Asia Pacific, Latin America, and Canada at G.D. Searle & Company. From 1991 to 1998, Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc., and Wyeth. Mr. Walbert received his B.A. in business from Muhlenberg College. In addition to the Egalet board of directors, Mr. Walbert serves on the XOMA Ltd., Sucampo Pharmaceuticals, Inc., Biotechnology Industry Organization (BIO), Illinois Biotechnology Industry Organization (iBIO), ChicagoNEXT and Greater Chicago Arthritis Foundation boards. Mr. Walbert was appointed by Illinois Governor Pat Quinn to the Illinois Innovation Council. Elaine Hochberg Ms. Hochberg has served as a member of our board of directors since April 2017. Ms. Hochberg has been the managing partner of Elaran, LLC, a business strategy and management firm, since 2016. She served in various positions of increasing responsibility at Forest Laboratories, LLC from 1997 to 2014, including as executive vice president – international, strategic planning and government affairs from 2013 to 2014, as executive vice president – US sales and marketing from 2010 to 2013 and as chief commercial officer from 2007 to 2013. Prior to that, Ms. Hochberg served in various roles at Wyeth Ayerst Laboratories. She serves on the board of Akcea Therapeutics, Inc., as well as the boards of several nonprofit corporations. Ms. Hochberg earned her BA and MBA from Columbia University. Nicholas Nicolaides, PhD Dr. Nicolaides has been on our board of directors since joining in April of 2015. He is the president and co-founder of Morphotek, a biopharmaceutical company specializing in the development of protein and antibody products for treating cancer, inflammation and infectious disease. Dr. Nicolaides’ post-graduate research at Johns Hopkins Medical School was the basis for the company’s inception. In the spring of 2007, Morphotek was acquired by Eisai Co. Ltd, a global health care pharmaceutical company. Prior to co-founding Morphotek, Dr. Nicolaides was the director of research at Magainin Pharmaceuticals, where his research focused on the development of bio-therapeutics to treat respiratory disease. He is a trained molecular geneticist and has authored a number of scientific papers on the molecular and genetic basis of cancer and respiratory diseases. He received his B.S. in biology at St. Joseph’s University, his Ph.D. in human genetics at Thomas Jefferson University and continued his training as a Fellow in Oncology at Johns Hopkins University. Dr. Nicolaides is an author on more than 50 original publications and is an inventor on numerous patents for developing bio-based therapies and therapeutic compositions. John Osborn Mr. Osborn has been a member of our board of directors since joining in April 2015. An experienced life sciences industry executive, Mr. Osborn was general counsel for a decade with Fortune 1000 biopharmaceutical company Cephalon, Inc. and held senior posts with Onyx Pharmaceuticals, Dendreon, US Oncology and DuPont Merck Pharmaceuticals. He has substantial experience in government affairs and public policy, having served with the U.S. Department of State during the George H.W. Bush administration, and from 2008 to 2011 he was a member of the bipartisan United States Advisory Commission on Public Diplomacy. Mr. Osborn currently is a senior advisor with the international law firm Hogan Lovells, and an industry advisor with the healthcare and consumer group of the global private equity firm Warburg Pincus. He has held faculty appointments at Oxford, Princeton and the University of Washington, and is a member of the Council on Foreign Relations, the American Law Institute, the advisory boards of QPID Health, Inc. and the University of Michigan Life Sciences Institute. Mr. Osborn received his undergraduate degree in economics and history from the University of Iowa, his law degree from the University of Virginia School of Law, and his master’s degree in international public policy from The Johns Hopkins University School of Advanced International Studies. Robert Radie Mr. Radie is president, chief executive officer and a member of Egalet’s board of directors and has been since March 2012. Mr. Radie has had a successful career with more than three decades in the industry and has been responsible for the sale of five companies. In 2005 Mr. Radie led the sale of Vicuron Pharmaceuticals to Pfizer for $1.9 billion and most recently he was responsible for the sale of Topaz Pharmaceuticals Inc. to Sanofi Pasteur for an undisclosed amount. Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Prestwick Pharmaceuticals, Inc., Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and served as a director of Affinium Pharmaceuticals, Ltd. from July 2012 to March 2014, when a majority of Affinium’s assets were acquired by a third party. Mr. Radie began his career in the life sciences at Eli Lilly and Company where he worked for 18 years in sales and marketing positions with increasing levels of responsibility. Mr. Radie serves on the board of Paratek Pharmaceuticals, a biopharmaceutical company, Pennsylvania Bio, an industry group supporting Pennsylvania life sciences companies, Veloxis, a private commercial-stage company, and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. Mr. Radie received his B.S. in chemistry from Boston College.